Axiall Corp (AXLL) versus Enzymotec (ENZY) Head to Head Analysis
Axiall Corp (NYSE: AXLL) and Enzymotec (NASDAQ:ENZY) are both basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Insider & Institutional Ownership
27.9% of Enzymotec shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Axiall Corp has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Enzymotec has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Axiall Corp and Enzymotec, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Enzymotec has a consensus target price of $8.00, suggesting a potential downside of 30.13%. Given Enzymotec’s higher probable upside, analysts plainly believe Enzymotec is more favorable than Axiall Corp.
Axiall Corp pays an annual dividend of $0.64 per share and has a dividend yield of 1.9%. Enzymotec does not pay a dividend. Axiall Corp pays out -5.0% of its earnings in the form of a dividend.
Valuation and Earnings
This table compares Axiall Corp and Enzymotec’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Enzymotec||$47.01 million||5.59||-$4.56 million||($0.29)||-39.48|
Axiall Corp has higher revenue, but lower earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than Axiall Corp, indicating that it is currently the more affordable of the two stocks.
This table compares Axiall Corp and Enzymotec’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Axiall Corp Company Profile
Axiall Corporation (Axiall) is a manufacturer and international marketer of chemicals and building products. The Company operates through two segments: chlorovinyls and building products. Its products include chlorine, caustic soda, vinyl chloride monomer, siding and exterior accessories, and pipe and pipe fittings, among others. The Company’s chlorovinyls segment produces a chain of products, including chlor-alkali and derivative products, such as vinyl resins, ethylene dichloride (or 1, 2 dichloroethane) (EDC), chlorinated solvents, calcium hypochlorite, hydrochloric acid (HCL) and phosgene derivatives, and compound products, such as vinyl compounds and compound additives and plasticizers. The Company’s building products segment consists of over two primary product groups: window and door profiles and trim, moldings and deck products, and outdoor building products, which includes siding and exterior accessories, pipe and pipe fittings.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Receive News & Ratings for Axiall Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axiall Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.